SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (262)9/19/2002 5:17:13 PM
From: scaram(o)uche  Read Replies (2) of 1840
 
As I've said before..... antigen-specific T cells are INCREDIBLE fighting machines. Tumor-specific T cells that recognize TRUE cancer-specific antigens (such as those on MCA-induced fibrosarcomas) absolutely kick butt after passive transfer.

So....... from my perspective...... if in vitro-generated cells became the predominate circulating population *and* if Rosenberg et al. aren't full of it, the fact that cures weren't obtained would imply that antigen-negative cancer cells were either pre-existing or arose at a rate that makes this approach problematic. If they aren't full of it, then it's simply an issue of finding enough antigens, of generating a pool of specificities such that it's impossible for "antigen negative" to exist. This is certainly a concept that Rosenberg et al. focus on, with melanoma vaccines.

With thought leaders like Rosenberg behind studies and funding of CMI against cancers, we've gone almost nowhere in twenty five years.

Enlightenment just ekes out.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News